The effect of denosumab on minimum 3-years bone mineral density (BMD) changes in patients with osteoporotic hip fractures: a propensity score matching analysis
Authors' conclusion
Denosumab significantly increased lumbar spine and total hip BMD in patients with hip fractures, with comparable efficacy to that in other than hip fracture patients.
Study context
- Population
- Patients with osteoporosis treated with denosumab for at least 3 years, including patients with hip fractures122 per group after matching
- Participants
- 371 patients
- Exposure
- Denosumab for at least 3 years in hip fracture vs other than hip fracture patients
- Hip fracturen = 122
- Other than hip fracturen = 122reference
- Outcome
- BMD changes in the lumbar spine, total hip and femoral neck; additional hip fracture incidence
Methodological details1:1 propensity score matching
- 1:1 propensity score matching
Main finding
As reported in the abstract
- Significant annual increases in lumbar spine and total hip BMD in both groups, with no significant differences between them after matching
- Femoral neck BMD increased significantly only in the first year
- Matched cohort
Observational data: associations, not effects.
Further findings
Additional hip fractures
- Incidence did not differ significantly between the groups
BMD increase, medication-naïve vs prior anti-osteoporosis medication (subgroup)
- Effect of denosumab on BMD increase more pronounced in patients without previous anti-osteoporosis medication
Original publication
The effect of denosumab on minimum 3-years BMD changes in patients with osteoporotic hip fractures: a propensity score matching analysis. Osteoporos Int. Published 13 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →